SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

$PMV is trending as the community rallies around its meme-driven culture and long-term vision for 2026, emphasizing community engagement and a fun, 'infected' vibe. Despite broader market dips, $PMV holders express strong conviction and are actively spreading awareness, aiming to establish a dominant meme presence in the crypto space. The community highlights the project's organic growth and unique meme-focused approach.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to speculation about its potential inclusion in the S&P 500, sparking intense debate; while some celebrate the possible milestone, others express concerns about the company's fundamentals and question its high valuation amidst auto loan delinquency worries, with opinions polarized between bullish and bearish stances.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu ($SAILANA) is trending due to a strong community rallying around the project, emphasizing its potential for significant growth and drawing comparisons to early Shiba Inu. Discussions highlight upcoming utility, the launch of WolfSWAP, and long-term goals, with the community actively pushing for decentralization and dismissing the influence of KOLs. The "Wolfpack" community is known for its unwavering support, frequently trending on social platforms.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending as the community rallies around aggressive token burns and network upgrades, aiming to reduce supply and revive the ecosystem. Community members are actively discussing potential price targets and the impact of Do Kwon's legal situation, while some express caution and skepticism about the sustainability of the recent price surge.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TREASURE GLOBAL INC ($TGL) is trending due to a recent reverse stock split and subsequent price surge, leading to discussions of a potential short squeeze. The community is actively debating price targets and comparing it to similar plays like $SMX, while also highlighting the stock's low float and potential catalysts related to its payment network.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

CVKD is trending due to strong buyer conviction and signs of a potential breakout, with bulls setting sights on higher targets. Community members are actively discussing the bullish setup and positive technicals, highlighting the rally's momentum. The stock, a low-float healthcare microcap, is perceived as catalyst-driven and capable of significant moves.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls ($RLS) is gaining attention as a newer crypto on Coinbase, with the community highlighting its potential for significant gains due to its relatively low market cap and limited availability on exchanges. Some traders are pointing to technical indicators, such as a potential golden cross, as signs of an impending breakout, while others discuss its initial debut price and possible upcoming catalysts. Chatter also mentions the possibility of market orders opening up soon.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following positive Phase 3 trial results for its breast cancer therapy, with community members discussing potential peak revenue and buyout scenarios. Jefferies updated its rating to Buy and significantly raised the price target, fueling bullish sentiment. The community is also closely watching for further data releases and FDA updates.

HSBC Holdings Plc engages in the provision of banking and financial services. It operates through the following business segments: Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, Global Private Banking, and Corporate Centre. The Retail Banking and Wealth Management segment consists of retail banking, wealth management, asset management, and insurance. The Commercial Banking segment offers banking products and services. The Global Banking and Markets segment includes transaction banking, financing, advisory, capital markets, and risk management services. The Global Private Banking offers transaction banking, financing, advisory, capital markets and risk management services to high-net-worth individuals and families. The Corporate Centre segment is involved in central treasury, including balance sheet management, other legacy businesses, interests in associates and joint ventures, central stewardship costs, and the UK bank levy. The company was founded on January 1, 1959 and is headquartered in London, the United Kingdom.

HSBC Holdings plc - ADR

HSBC Holdings plc

HSBC is trending as the community discusses its AI initiatives, including partnerships with Mistral AI and quantum computing advancements for bond trading, alongside its debt market strategies. Community members are weighing the bank's Asia-focused expansion, restructuring efforts, and capital returns, while also considering the implications of leadership changes and potential impacts of global economic factors. Some investors are monitoring HSBC's strategic shifts, such as exiting certain markets and business lines, while others are focused on unusual options activity and technical indicators to inform their trading decisions.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as community members discuss its potential for a significant price increase, drawing comparisons to Zcash's recent surge and highlighting its resilience amidst market volatility. Some investors are exploring Keeta, framing it as complementary infrastructure for Bitcoin Cash, emphasizing its high-throughput capabilities and institutional-grade compliance features. The community expresses optimism for future growth while acknowledging differing opinions on its long-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports...

What is HC Wainwright's Estimate for CRDF FY2025 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Cardiff Oncology in a note issued to investors on Wednesday...

Cardiff Oncology (NASDAQ:CRDF) Issues Quarterly Earnings Results

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20...

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments PR Newswire VANCOUVER, BC, Dec...

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion...

Cardiff Oncology (CRDF, $5.73) Aroon Indicator entered an Uptrend on April 01, 2024.

Over the last three days, A.I.dvisor has detected that CRDF's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Cardiff Oncology (CRDF, $5.73) entered Uptrend as Momentum indicator ascends above 0 level on Apr 01, 2024

This indicator may be signaling CRDF's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Cardiff Oncology Inc

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

CRDF
Cardiff Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRDF News

CRDFCardiff Oncology Inc